CSIMarket
 


Nascent Biotech Inc  (NBIO)
Other Ticker:  
 

Nascent Biotech Inc's Working Capital Ratio

NBIO's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Working Capital Ratio deteriorated to 1.05 above company average Working Capital Ratio.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Working Capital Ratio than Nascent Biotech Inc in third quarter 2023. While Working Capital Ratio total ranking has improved so far during the III Quarter 2023 to 679, from total ranking in the second quarter 2023 at 2318.

Explain Working Capital Ratio
How much in Current Assets NBIO´s has?
What is the value of NBIO´s Current Liabilities?


NBIO Working Capital Ratio (Dec 31 2023)
III. Quarter
(Sep 30 2023)
II. Quarter
(Jun 30 2023)
I. Quarter
(Mar 31 2023)
IV. Quarter
(Dec 31 2022)
III. Quarter
Y / Y Current Liabilities Change -68.46 % -58.35 % -23.83 % 99.66 % 60.87 %
Y / Y Current Assets Change 13.41 % -13.18 % -56.95 % 141.91 % -24.73 %
Working Capital Ratio MRQ 1.05 1.05 0.06 0.16 0.29
NBIO's Total Ranking # 679 # 2318 # 4629 # 4673 # 2427
Seq. Current Liabilities Change -38.83 % -19.36 % -20.45 % -19.63 % -19.21 %
Seq. Current Assets Change -38.46 % 1221.13 % -69.05 % -54.93 % -52.89 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 44
Healthcare Sector # 102
Overall Market # 679


Working Capital Ratio Statistics
High Average Low
4.47 0.55 0
(Sep 30 2017)   (Jun 30 2020)




Financial Statements
Nascent Biotech Inc's Current Liabilities $ 1 Millions Visit NBIO's Balance sheet
Nascent Biotech Inc's Current Assets $ 1 Millions Visit NBIO's Balance sheet
Source of NBIO's Sales Visit NBIO's Sales by Geography


Cumulative Nascent Biotech Inc's Working Capital Ratio

NBIO's Working Capital Ratio for the trailling 12 Months

NBIO Working Capital Ratio

(Dec 31 2023)
III. Quarter
(Sep 30 2023)
II. Quarter
(Jun 30 2023)
I. Quarter
(Mar 31 2023)
IV. Quarter
(Dec 31 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth -68.46 % -58.35 % -23.83 % 99.66 % 60.87 %
Y / Y Current Assets TTM Growth 13.41 % -13.18 % -56.95 % 141.91 % -24.73 %
Working Capital Ratio TTM 0.46 0.34 0.3 0.29 0.31
Total Ranking TTM # 2308 # 3626 # 3869 # 4085 # 4691
Seq. Current Liabilities TTM Growth -38.83 % -19.36 % -20.45 % -19.63 % -19.21 %
Seq. Current Assets TTM Growth -38.46 % 1221.13 % -69.05 % -54.93 % -52.89 %


On the trailing twelve months basis NBIO Current Assets increased by 13.41 % in III Quarter 2023 year on year, while Current Liabilities plummeted to $1 millions, this led to increase in in Nascent Biotech Inc's Working Capital Ratio to 0.46, above NBIO average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 220 other companies have achieved higher Working Capital Ratio than Nascent Biotech Inc. While Working Capital Ratio overall ranking has improved so far to 793, from total ranking during the twelve months ending second quarter 2023 at 2643.

Explain Working Capital Ratio
How much in Current Assets NBIO´s has?
What is the value of NBIO´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 221
Healthcare Sector # 505
Within the Market # 679


trailing twelve months Working Capital Ratio Statistics
High Average Low
1.61 0.36 0
(Dec 31 2017)   (Jun 30 2020)




Companies with similar Working Capital Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioDec 31 2023 MRQ Current AssetsDec 31 2023 MRQ Current Liabilities
Catalyst Pharmaceuticals Inc   2.88 $ 219.329  Millions$ 76.063  Millions
Amicus Therapeutics inc   2.88 $ 483.061  Millions$ 167.689  Millions
Edesa Biotech Inc   2.84 $ 5.416  Millions$ 1.909  Millions
Ampio Pharmaceuticals inc   2.73 $ 5.736  Millions$ 2.102  Millions
Hutchmed china Limited  2.72 $ 1,096.839  Millions$ 403.027  Millions
Bioxcel Therapeutics Inc   2.65 $ 72.143  Millions$ 27.267  Millions
Talphera Inc   2.56 $ 11.556  Millions$ 4.512  Millions
Acurx Pharmaceuticals inc   2.53 $ 7.709  Millions$ 3.042  Millions
Biomarin Pharmaceutical Inc  2.51 $ 2,956.088  Millions$ 1,177.024  Millions
Insmed Inc  2.51 $ 929.063  Millions$ 370.021  Millions
Catalent Inc   2.48 $ 2,570.000  Millions$ 1,036.000  Millions
Alimera Sciences Inc   2.39 $ 52.423  Millions$ 21.913  Millions
Entrada Therapeutics Inc   2.33 $ 369.771  Millions$ 158.796  Millions
Evolus Inc   2.33 $ 112.421  Millions$ 48.291  Millions
Beigene ltd   2.32 $ 4,203.414  Millions$ 1,810.113  Millions
Aquestive Therapeutics Inc   2.24 $ 40.966  Millions$ 18.308  Millions
Jazz Pharmaceuticals Plc  2.24 $ 3,435.428  Millions$ 1,536.692  Millions
Eterna Therapeutics Inc   2.20 $ 9.599  Millions$ 4.357  Millions
Eyenovia inc   2.17 $ 20.707  Millions$ 9.530  Millions
Nature s Sunshine Products inc   2.16 $ 165.817  Millions$ 76.753  Millions
23andme Holding Co  2.15 $ 309.959  Millions$ 144.139  Millions
Immunic Inc   2.12 $ 52.534  Millions$ 24.729  Millions
Teva Pharmaceutical Industries Limited  2.10 $ 12,485.000  Millions$ 5,941.000  Millions
Ptc Therapeutics inc   2.02 $ 1,218.629  Millions$ 603.100  Millions
Perrigo Company Plc  1.99 $ 2,832.900  Millions$ 1,422.800  Millions
Elite Pharmaceuticals Inc   1.94 $ 37.164  Millions$ 19.159  Millions
Vaxxinity Inc   1.89 $ 33.230  Millions$ 17.605  Millions
Igc Pharma Inc   1.85 $ 3.583  Millions$ 1.936  Millions
Ainos Inc   1.85 $ 2.473  Millions$ 1.337  Millions
Assertio Holdings inc   1.83 $ 171.062  Millions$ 93.443  Millions

Date modified: 2024-02-16T22:27:40+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com